Evidence map›Paper›PMID 33632183›Full record

ArticleBMC pulmonary medicine2021

Inspiratory flow profile and usability of the NEXThaler, a multidose dry powder inhaler, in asthma and COPD.

Alfredo Chetta, Arzu Yorgancioglu, Mario Scuri, Sara Barile, Daniele Guastalla, P N Richard Dekhuijzen

Abstract read
In one paragraph

Article in BMC pulmonary medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. NEXThalerJournal of clinical medicine · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Feedback systems in multi-dose dry powder inhalers.Postepy dermatologii i alergologii · 2023
    Review
  7. Article
  8. Measuring Peak Inspiratory Flow in Patients with Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alfredo ChettaRespiratory Disease and Lung Function Unit, Department of Medicine and Surgery, University of Parma, Parma, Italy. alfredoantonio.chetta@unipr.it.
Arzu YorganciogluDepartment of Pulmonology, Medical Faculty, Celal Bayar University, Manisa, Turkey.
Mario ScuriChiesi Farmaceutici SpA, Parma, Italy.
Sara BarileChiesi Farmaceutici SpA, Parma, Italy.
Daniele GuastallaChiesi Farmaceutici SpA, Parma, Italy.
P N Richard DekhuijzenRadboud University Medical Center, Nijmegen, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundInhaler selection is important when managing respiratory conditions; a patient's inhalation technique should be appropriate for the selected device, and patients should ideally be able to use a device successfully regardless of disease severity. The NEXThaler is a multidose dry-powder inhaler with a breath-actuated mechanism (BAM) and dose counter that activates only following inhalation, so effectively an 'inhalation counter'. We assessed inspiratory flow through the NEXThaler in two studies and examined whether inhalation triggered the BAM.

methodsThe two studies were open-label, single-arm, and single visit. One study recruited patients with asthma aged ≥ 18 years; the other recruited patients with chronic obstructive pulmonary disease (COPD) aged ≥ 40 years. All patients inhaled twice through a placebo NEXThaler. The inspiratory profile through the device was assessed for each inhalation using acoustic monitoring, with flow at and time to BAM firing, peak inspiratory flow (PIF), and total inhalation time assessed.

resultsA total of 40 patients were enrolled in the asthma study: 20 with controlled asthma and 20 with partly controlled/uncontrolled asthma. All patients were able to trigger the BAM, as evidenced by the inhalation counter activating on closing the device. Mean flow at BAM firing following first inhalation was 35.0 (range 16.3-52.3) L/min; mean PIF was 64.6 (35.0-123.9) L/min. A total of 72 patients were enrolled in the COPD study, with data analysed for 69 (mean forced expiratory volume in 1 s 48.7% predicted [17-92%]). As with the asthma study, all patients, regardless of airflow limitation, were able to trigger the BAM. Mean flow at BAM firing following first inhalation was 41.9 (26.6-57.1) L/min; mean PIF was 68.0 (31.5-125.4) L/min. Device usability was rated highly in both studies, with 5 min sufficient to train the patients, and a click heard shortly after inhalation in all cases (providing feedback on BAM firing).

conclusionsInhalation flows triggering the BAM in the NEXThaler were similar between patients with controlled and partly controlled/uncontrolled asthma, and were similar across COPD airflow limitation. All enrolled patients were able to activate the device.

Indexed as

Administration, InhalationAdolescentAdultAgedAsthmaDry Powder InhalersFemaleHumansLungMaleMiddle AgedPulmonary Disease, Chronic ObstructiveRespiratory Function TestsRespiratory TherapyYoung AdultAsthmaBreath-actuated mechanismChronic obstructive pulmonary diseaseDry powder inhalersInspiratory flow

Identifiers

PMID33632183
PMCPMC7905605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.